Revvity (RVTY) Projected to Post Earnings on Monday

Revvity (NYSE:RVTY - Get Free Report) is anticipated to announce its Q1 2025 earnings results before the market opens on Monday, April 28th. Analysts expect Revvity to post earnings of $0.95 per share and revenue of $662.30 million for the quarter. Revvity has set its FY 2025 guidance at 4.900-5.000 EPS.

Revvity (NYSE:RVTY - Get Free Report) last announced its quarterly earnings results on Friday, January 31st. The company reported $1.42 earnings per share for the quarter, beating analysts' consensus estimates of $1.37 by $0.05. Revvity had a return on equity of 7.68% and a net margin of 9.81%. During the same period in the previous year, the company earned $1.25 earnings per share. On average, analysts expect Revvity to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Revvity Price Performance

NYSE:RVTY traded down $0.81 during mid-day trading on Friday, hitting $94.33. 951,959 shares of the company's stock traded hands, compared to its average volume of 911,357. The firm's 50 day simple moving average is $105.22 and its 200 day simple moving average is $113.28. The company has a market cap of $11.33 billion, a PE ratio of 42.69, a price-to-earnings-growth ratio of 3.82 and a beta of 1.07. Revvity has a 1 year low of $88.53 and a 1 year high of $129.50. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.03 and a current ratio of 3.60.

Revvity Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, August 8th. Shareholders of record on Friday, July 18th will be issued a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a yield of 0.30%. Revvity's dividend payout ratio (DPR) is presently 12.67%.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on RVTY shares. Raymond James reissued an "outperform" rating and set a $145.00 price objective (up previously from $140.00) on shares of Revvity in a research note on Monday, February 3rd. KeyCorp lifted their price target on Revvity from $132.00 to $145.00 and gave the company an "overweight" rating in a report on Monday, February 3rd. Barclays lowered their target price on shares of Revvity from $140.00 to $110.00 and set an "overweight" rating for the company in a report on Thursday, April 10th. Robert W. Baird cut their price target on shares of Revvity from $141.00 to $127.00 and set an "outperform" rating on the stock in a research note on Monday. Finally, Wells Fargo & Company lowered their price objective on shares of Revvity from $130.00 to $102.00 and set an "equal weight" rating for the company in a research note on Thursday, April 17th. Four equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $130.50.

Insider Transactions at Revvity

In other Revvity news, insider Joel S. Goldberg sold 15,170 shares of the company's stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $126.73, for a total transaction of $1,922,494.10. Following the sale, the insider now owns 33,400 shares in the company, valued at $4,232,782. This represents a 31.23 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.68% of the company's stock.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.